Breast cancer: State of the art and new findings;Das Mammakarzinom: State of the Art und Neuigkeiten

Geburtshilfe und Frauenheilkunde

Volumn 72, Issue 3, 2012, Pages 215-224

  Melcher, C ^a   Scholz, C ^a   Jager B ^b   Hagenbeck, C ^a   Rack, B ^b   Janni, W ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

breast cancer; chemotherapy; endocrine therapy; molecular genetic subtypes; prognosis; radiotherapy; targeted therapy

Indexed keywords

BEVACIZUMAB; DENOSUMAB; PROTEIN TYROSINE KINASE INHIBITOR;

ADJUVANT CHEMOTHERAPY; BONE METASTASIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL PRACTICE; HUMAN; LYMPH NODE; REVIEW;

EID: 84859375965     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0031-1298320     Document Type: Review

References (50)

1. Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol: 2011; 22 1736 1747
2. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol: 2000; 182 311 322 (Pubitemid 30054364)
3. Untch M, Gerber B, Möbus V et al. Zurich consensus: statement of German experts on St. Gallen conference 2011 on breast cancer (Zurich 2011). Geburtsh Frauenheilk: 2011; 71 381 390
4. AGO-Empfehlungen Gynäkologische Onkologie - Kommission Mamma. Deutsche Version 11.1.0. http://www.ago-online.org last access: 7.11.2011
5. Cristofanilli M. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Semin Oncol: 2006; 33 3 09 S9 S14
6. Rack B. Prognostic relevance of circulating tumor cells in the peripheral blood of primary breast cancer patients. SABCS: 2010; Abstract S6-5
7. Hartkopf A, Banys M, Krawczyk N et al. Circulating tumor cells in early-stage breast cancer. Geburtsh Frauenheilk: 2011; 12 1067 1072
8. Kaufmann M, von Minckwitz G, Bear HD et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol: 2007; 18 1927 1934 (Pubitemid 350286227)
9. Kaufmann M, Hortobagyi GN, Goldhirsch A et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol: 2006; 24 1940 1949 (Pubitemid 46638994)
10. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol: 1998; 16 2672 2685 (Pubitemid 28363030)
11. Kaufmann M. Long-term results from the neoadjuvant GeparDuo trial. J Clin Oncol: 2010; 28 15 Abstract 537
12. Kaufmann M, von Minckwitz G, Smith R et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol: 2003; 21 2600 2608 (Pubitemid 46606344)
13. Kreienberg R, Kopp I, Albert U. Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms, 2008. http://www.dggg.de/leitlinien Stand: 7.11.2011
14. von Minckwitz G, Blohmer JU, Costa S et al. Neoadjuvant chemotherapy adapted by interim response improves overall survival of primary breast cancer patients - results of the GeparTrio trial. SABCS: 2011; Abstract S3-2
15. OHiggins N, Linos DA, Blichert-Toft M et al. European Guidelines for Quality Assurance in the surgical Management of mammographically detected Lesions. In: Perry N. et al., eds. European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis. Office for Official Publications of the European Communities: 2006; 315 321
16. Fisher B, Anderson S, Bryant J et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med: 2002; 347 1233 1241 (Pubitemid 35176242)
17. Veronesi U, Cascinelli N, Mariani L et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med: 2002; 347 1227 1232 (Pubitemid 35176241)
18. Blamey RW. The role of the radiologist in breast diagnosis: a surgeons personal view. Clin Radiol: 1998; 53 393 395 (Pubitemid 28282593)
19. Blichert-Toft M, Smola MG, Cataliotti L et al. on behalf of the European Society of Surgical Oncology Principles and guidelines for surgeons - management of symptomatic breast cancer. Ann Chir Gynaecol: 1998; 87 101 109
20. Palesty JA, Foster JM, Hurd TC et al. Axillary recurrence in women with a negative sentinel lymph node and no axillary dissection in breast cancer. J Surg Oncol: 2006; 93 129 132 (Pubitemid 43235258)
21. Smidt ML, Janssen CM, Kuster DM et al. Axillary recurrence after a negative sentinel node biopsy for breast cancer: incidence and clinical significance. Ann Surg Oncol: 2005; 12 29 33 (Pubitemid 40486638)
22. Fleissig A, Fallowfield LJ, Langridge CI et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat: 2006; 95 279 293
23. Krag DN, Anderson SJ, Julian TB et al. Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients. J Clin Oncol: 2010; 28 18 (Suppl.): Abstract LBA505
24. Giuliano AE, Hunt KK, Ballman KV et al. Axillary dissection vs. no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA: 2011; 305 569 575
25. Galimberti V, Cole BF, Zurrida S et al. International, and B.C.S.G.T.-Investigators Update of International Breast Cancer Study Group trial 23-01 to compare axillary dissection versus no axillary dissection in patients with clinically node negative breast cancer and micrometastases in the sentinel node. SABCS: 2011; Abstract S3-1
26. Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol: 2003; 21 976 983 (Pubitemid 46594124)
27. Roche H, Fumoleau P, Spielmann M et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS01 trial. J Clin Oncol: 2006; 24 5664 5671 (Pubitemid 46631307)
28. Kaufmann M, Rody R. Breast cancer: reduced mortality by early detection and adjuvant therapy. Geburtsh Frauenheilk: 2009; 69 218 232
29. Boccardo F, Rubagotti A, Guglielmini P et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol: 2006; 17 07 vii10 vii14 (Pubitemid 43985170)
30. Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet: 2007; 369 559 570
31. Belkacemi Y, Laharie-Mineur H, Gligorov J et al. [Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer]. Cancer Radiother: 2007; 11 266 275 (Pubitemid 47465024)
32. Van de Steene J, Vinh-Hung V, Cutuli B et al. Adjuvant radiotherapy for breast cancer: effects of longer follow-up. Radiother Oncol: 2004; 72 35 43 (Pubitemid 38952857)
33. Clarke R. 21st century challenges in radiation protection and shielding: draft 2005 recommendations of ICRP. Radiat Prot Dosimetry: 2005; 115 (1-4) 10 15 (Pubitemid 43103375)
34. Antonini N, Jones H, Horiot JC et al. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. Radiother Oncol: 2007; 82 265 271 (Pubitemid 46341468)
35. Truong PT, Lee J, Kader HA et al. Locoregional recurrence risks in elderly breast cancer patients treated with mastectomy without adjuvant radiotherapy. Eur J Cancer: 2005; 41 1267 1277 (Pubitemid 40813002)
36. Fasching PA, Fehm T, Janni W et al. Breast cancer therapy - a state of the art review. Geburtsh Frauenheilk: 2010; 11 875 886
37. Thompson AM, Jordan LB, Quinlan P et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res: 2010; 12 R92
38. Stockler M, Wilcken NR, Ghersi D et al. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev: 2000; 26 151 168 (Pubitemid 30330662)
39. Klijn JG, Biamey RW, Boccardo F et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol: 2001; 19 343 353 (Pubitemid 32112845)
40. Liedtke C, Wolf MK, Kiesel L. New concepts for targeted systemic therapy in breast cancer. Geburtsh Frauenheilk: 2010; 70 625 633
41. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol: 2001; 19 2596 2606 (Pubitemid 32451796)
42. Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J: 2001; 7 377 387 (Pubitemid 33759002)
43. Stopeck AT, Lipton A, Body JJ et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol: 2010; 28 5132 5139
44. F. N. World Cancer Research Fund and American Institute for Cancer Research ed. Physical activity and the prevention of cancer. A global perspective. Washington, DC AICR: 2007
45. Andergassen U, Rack B, Annecke K et al. Obesity and tumor characteristic sin nodal-positive early-stage breast cancer: Results of the German ADEBAR study. J Clin Oncol: 2010; 28 (Suppl.) 15s (Abstr. 591)
46. Chlebowski RT et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Womens Intervention Nutrition Study. J Natl Cancer Inst: 2006; 98 1767 1776 (Pubitemid 46017928)
47. Kleeberg UR. Körperliche Aktivität und Brustkrebs - Prävention und Nachsorge. Geburtsh Frauenheilk: 2009; 69 423 425
48. Khatcheressian JL, Wolff AC, Smith TJ et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol: 2006; 24 5091 5097 (Pubitemid 46631413)
49. Palli D, Russo A, Saieva C et al. Intensive vs. clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council Project on Breast Cancer Follow-up. JAMA: 1999; 281 1586 (Pubitemid 29211763)
50. The GIVIO Investigators Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. JAMA: 1994; 271 1587 1592